LEO Pharma and X‑Chem Enter Into Discovery Research Agreement

July 6, 2021

Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti- inflammatory Applications BALLERUP, Denmark, and WALTHAM, Mass., US;...


X‑Chem Announces OpenDEX DNA-Encoded Library Screening

May 11, 2021

Flexible and Cost-Effective Solution for Screening Billions of Small Molecules WALTHAM, Mass.; May 11, 2021 (Business Wire) – X-Chem, the...


Arbutus Biopharma, X‑Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

April 1, 2021

Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of...


X‑Chem Enters into Multitarget Oncology Discovery Research Collaboration and License Agreement with Genentech

February 2, 2021

 Collaboration Includes Licensing of Preclinical Small Molecule Program  WALTHAM, Mass.; Feb. 2, 2021 (Business Wire) – X-Chem, Inc., a global...


X‑Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range

January 26, 2021

Acquisition allows X-Chem to offer a more comprehensive, integrated, screen-to-lead drug discovery process to pharma and biotech clients IntelliSyn’s Founder...


Servier and X‑Chem Announce Drug Discovery Collaboration in Neurological Diseases

January 6, 2021

Paris and Waltham, Mass.; Jan. 6, 2021 (Business Wire) – Servier, a global pharmaceutical Group and X-Chem, Inc., a privately...


X‑Chem Announces Licensing of Second Drug Discovery Program to Otsuka

January 4, 2021

Waltham, Mass – January 4, 2020 – X-Chem Inc. (X-Chem), the global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, announced today that Otsuka Pharmaceutical Co., Ltd.…